Glaukos Files Pre-Market Application For Intraocular Pressure Device
- Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System.
- Related Content: William Blair Downgrades Glaukos After Disappointing CMS Rate
- The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy.
- It includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents across a span of up to approximately six clock hours around Schlemm's canal, the eye's primary drainage channel.
- The iStent infinite trial at 12 months showed that 76% of subjects achieved a 20% or greater reduction in mean diurnal IOP from baseline on the same or lower ocular hypotensive medication burden.
- Over 50% of subjects achieved Month 12 IOP reduction greater than 30%.
- Subjects also achieved a 13% reduction in mean medication burden at 12 months.
- Price Action: GKOS shares traded 0.48% lower at $59.52 on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs glaucoma medical devicesNews Health Care FDA General
